Table 3.

Clinical and molecular characteristics of study cohort

Patient	Status	Age at Dx (years)	Blast%	G-banding Karyotype	Molecular diagnostic (28 translocations)	AML prognostic marker
1	P	26	55	46,XX [20]	Negative	NPM1 (MutA) positive, FLT3-ITD positive
	R		30	46,XX [20]	Negative	NPM1 (MutA) positive, FLT3-ITD negative
2	P	17	> 80	46,XX [20]	Negative	NPM1 negative, FLT3-ITD negative
	R		60	46,XX [20]	Negative	NPM1 negative, FLT3-ITD negative
3	P	43	91	46,XY [20]	Negative	NPM1 negative, FLT3-ITD negative
	R		94	46,XY [20]	Negative	NPM1 negative, FLT3-ITD negative
4	P	40	11	46,XY [20]	Negative	NPM1 negative, FLT3-ITD negative
	R		70	46,XY [20]	Negative	NPM1 negative, FLT3-ITD negative
5	P	51	54	46,XY [20]	Negative	NPM1 (MutA) positive, FLT3-ITD negative
	R		20	46,XY [20]	Negative	NPM1 (MutA) positive, FLT3-ITD negative
6	P	33	61	46,XX [20]	Negative	NPM1 negative, FLT3-ITD negative
	R		91	46,XX [20]	Negative	NPM1 negative, FLT3-ITD negative